First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    CVS Health Corporation

    CVS · 29 developments mapped · last assessed 2026-09-27

    Market Ontology has mapped 29 macro, policy, and market developments to CVS Health Corporation since 2026-08-30. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for CVS yet, so no modelled value is shown. The CVS valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run CVS on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for CVS. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary

      Increased prescription volume and formulary management fees for GLP-1 drugs, particularly with new oral treatments gaining PBM access.

      · Moves pharmacy services revenue growth, pbm profitability

    • Open question

      NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across Doses

      Potential for increased prescription volume for GLP-1 drugs (both branded and compounded) through its pharmacy benefit management (PBM) and retail pharmacy segments, but also pressure on PBM margins if compounded options gain significant traction.

      · Moves pharmacy script volume growth, pbm rebate dynamics, healthcare services utilization

    What changed, by assumption

    Pharmacy services revenue growth
    • 2026-09-18Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
    • 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage
    Prescription volume growth
    • 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage
    • 2026-09-18Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs
    • 2026-08-30Eli Lilly GLP-1 Revenue Hits Nearly Two-Thirds of Sales Amid 45% Top-Line Growth
    Pharmacy benefit management revenue growth
    • 2026-09-18Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM Coverage
    Pbm segment growth rate
    • 2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands
    Pharmacy segment growth rate
    • 2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-07-09MarginBearishHHS OIG report on prior-authorization practices increases regulatory and legal risk for the company's Medicare Advantage segment.0.75

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-27US National Debt Crosses $40 Trillion as Annual Interest Reaches $1.25 Trillionwatch3-12m0.40
    2026-09-23Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli LillyBullish1-3m0.40
    2026-09-23Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market PushBullish1-3m0.40
    2026-09-23Novo Rebrands to 'Novo' and Deploys Oral GLP-1 Pill in Market Share Defensemixed3-12m0.50
    2026-09-22Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYAwatch3-12m0.20
    2026-09-19Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuitymixed3-12m0.40
    2026-09-19Teva real-world data demonstrates UZEDY reduces emergency care and medical costsBullish1-5y0.30
    2026-09-19Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductionsmixed3-12m0.50
    2026-09-19Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilizationmixed3-12m0.40
    2026-09-18Centene Posts $2.51 Q2 EPS as Medical Cost Turnaround Offsets 8%-9% Medicaid Shrinkagewatch3-12m0.30
    2026-09-18Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formularyBullish1-3m0.70
    2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverageBullish1-3m0.70